CDMO - February 19, 2016
Recipharm makes €40m investment
Recipharm will invest €40m over the next three years to ensure state of-the-art solutions for serialisation processes. The move by the company comes as the announcement of the EU Falsified Medicines Directive (EUFMD) Safety Features Delegated Regulation is released. This means that the serialisation of licensed drug products will be a legal requirement for companies in the EU […]
Acquisition - January 16, 2016
Recipharm receives approval for acquisition of Nitin
Further to the company’s announcement on 20th October 2015 that Recipharm will acquire a majority stake (74%) in Nitin Lifesciences Limited, the Indian Foreign Investment and Promotion Board has now granted approval for this transaction to take place. Closing is expected to take place by the end of Q1 2016.
In a new job - January 10, 2016
New General Manager for Recipharm’s new subsidiary
Recipharm has appointed Yves Buelens to the position of General Manager for its wholly owned new subsidiary Kaysersberg Pharmaceuticals SAS. Yves Buelens has a Master in Pharmaceutical Sciences from the University of Brussels, Belgium and a specialisation as Industrial Pharmacist (QP). He brings a broad experience to the Group acquired in various roles in the pharmaceutical industry as well […]
Agreement - December 22, 2015
Recipharm signs agreement with Alcon
Recipharm signs manufacturing agreement with Alcon and acquires facility in France, adding new niche capabilities. Recipharm AB has entered into the previously announced strategic collaboration with Alcon, a Novartis company, and today signed a long term supply agreement whereby Recipharm will manufacture a range of ophthalmic products using Blow Fill Seal technology. As part of this collaboration, Recipharm will also […]
Agreement - December 17, 2015
Recipharm and LIDDS signs contract
Recipharm and LIDDS have signed an exclusive collaboration agreement regarding scale-up of the production process and commercial manufacture of Liproca Depot, LIDDS patented targeted treatment for prostate cancer. The agreement will be an important component for the upcoming Phase IIb study which is planned to start in 2016. In connection with the agreement, Recipharm invests […]
CDMO - November 10, 2015
Recipharm secures €25 million contract
Recipharm has signed an agreement with Daewoong, a Korean based pharmaceutical company with a strong presence in respiratory therapeutics, for a ten year extension of its existing contract, through to 2025, for the manufacture and supply of Erdosteine API. The finished Erdosteine product is manufactured by Daewoong Pharmaceutical at its Korean facilities. Under the terms of the new agreement, Daewoong […]
